Survival according to cytogenetic risk group for patients with t-AML or de novo AML treated by the German AML Cooperative Group (AMLCG).26
| . | No. of patients . | Median survival (mos) . | |||
|---|---|---|---|---|---|
| Karyotype . | t-AML (n = 121) . | de novoAML (n = 1511) . | t -AML . | de novoAML . | P . |
| Favorable | 29 | 306 | 27 | Not reached | .02 |
| Intermediate | 34 | 903 | 12 | 16 | .19 |
| Unfavorable | 58 | 302 | 6 | 7 | .006 |
| . | No. of patients . | Median survival (mos) . | |||
|---|---|---|---|---|---|
| Karyotype . | t-AML (n = 121) . | de novoAML (n = 1511) . | t -AML . | de novoAML . | P . |
| Favorable | 29 | 306 | 27 | Not reached | .02 |
| Intermediate | 34 | 903 | 12 | 16 | .19 |
| Unfavorable | 58 | 302 | 6 | 7 | .006 |